[Trial of the clinical use of mithramycin in treating testicular cancer].
The data on efficacy of mitramycin, an antitumor antibiotic in treatment of 32 patients with cancer of the testicle are presented. The objectively pronounced effect was observed in 37.5 per cent of the cases, mitramycin being effective in patients with tumors resistant to bleomycin, vinblastin and cis-dichlordiaminoplatinum. Nausea and vomiting were the most frequent side effects of mitramycin use. The hemorrhagic syndrome was recorded in 2 patients. The regimen of the mitramycin intravenous administration in a dose of 25--30 microgram/kg once in 2 days was well tolerated by the patients and may be recommended for the treatment of testicle cancer.
D000328:Adult; D002986:Clinical Trials as Topic; D004407:Dysgerminoma / Q000188:drug therapy; D006801:Humans; D008207:Lymphatic Metastasis; D008297:Male; D009362:Neoplasm Metastasis; D009373:Neoplasms, Germ Cell and Embryonal / Q000188:drug therapy; D008926:Plicamycin / Q000009:adverse effects / Q000627:therapeutic use*; D013724:Teratoma / Q000188:drug therapy; D013736:Testicular Neoplasms / Q000188:drug therapy*
D008926:Plicamycin
Opyt klinicheskogo primeneniia mitramitsina pri lechenii raka iaichka.